Expression of Galectin-3 in Normal and Malignant Thyroid Tissue by Quantitative PCR and Immunohistochemistry
暂无分享,去创建一个
M. Tötsch | K. Schmid | S. Sheu | C. Meier | A. Spiliopoulos | J. Robert | J. Feilchenfeldt | A. Frilling | A Frilling | M. Tötsch
[1] M. Ringel. Molecular Diagnostic Tests in the Diagnosis and Management of Thyroid Carcinoma , 2000, Reviews in Endocrine and Metabolic Disorders.
[2] E. Kimura,et al. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. , 2002, The Journal of clinical endocrinology and metabolism.
[3] M. Papotti,et al. Role of galectin-3 immunodetection in the cytological diagnosis of thyroid cystic papillary carcinoma. , 2002, European journal of endocrinology.
[4] Y. Vaishnav,et al. Determination of galectin-3 messenger ribonucleic Acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. , 2002, The Journal of clinical endocrinology and metabolism.
[5] M. Beesley,et al. Cytokeratin 19 and galectin‐3 immunohistochemistry in the differential diagnosis of solitary thyroid nodules , 2002, Histopathology.
[6] M. Niedziela,et al. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. , 2002, The Journal of clinical endocrinology and metabolism.
[7] K. Nabeshima,et al. Diagnostic utility of galectin‐3 and CD26/DPPIV as preoperative diagnostic markers for thyroid nodules , 2002, Diagnostic cytopathology.
[8] P. De Giuli,et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. , 2001, The Journal of clinical endocrinology and metabolism.
[9] A. Vecchione,et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions , 2001, The Lancet.
[10] W. Hopfenmüller,et al. [Expression of galectin-3 in thyroid gland and follicular cell tumors of the thyroid. A critical study of its possible role in preoperative differential diagnosis]. , 2001, Der Pathologe.
[11] W. Hopfenmüller,et al. Untersuchungen zur Expression von Galectin-3 im Schilddrüsengewebe und in Follikelzelltumoren der Schilddrüse Kritische Bewertung einer möglichen präoperativen differenzialdiagnostischen Nutzung , 2001, Der Pathologe.
[12] C. Shriver,et al. Expression of the Sodium Iodide Symporter and Thyroglobulin Genes Are Reduced in Papillary Thyroid Cancer , 2001, Modern Pathology.
[13] H. Inohara,et al. Down-regulation of galectin-3 suppresses tumorigenicity of human breast carcinoma cells. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.
[14] Rajnish A. Gupta,et al. 15S-Hydroxyeicosatetraenoic acid activates peroxisome proliferator-activated receptor gamma and inhibits proliferation in PC3 prostate carcinoma cells. , 2001, Cancer research.
[15] C. Meier. Thyroid nodules: pathogenesis, diagnosis and treatment. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.
[16] Y. Oertel,et al. Thyroid cytology and histology. , 2000, Bailliere's best practice & research. Clinical endocrinology & metabolism.
[17] M. Samii,et al. Solitary follicular thyroid carcinoma of the skull base and its differentiation from ectopic adenoma — review, use of galectin-3 and report of a new case , 2000, Clinical Neurology and Neurosurgery.
[18] S. Natsugoe,et al. Galectin-3 expression in various thyroid neoplasms and its possible role in metastasis formation. , 2000, Human pathology.
[19] K. Pienta,et al. Galectin-3 induces endothelial cell morphogenesis and angiogenesis. , 2000, The American journal of pathology.
[20] M. P. Martegani,et al. Galectin-3 and CD44v6 isoforms in the preoperative evaluation of thyroid nodules. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] V. Lazar,et al. Expression of the Na+/I- symporter gene in human thyroid tumors: a comparison study with other thyroid-specific genes. , 1999, The Journal of clinical endocrinology and metabolism.
[22] U. Lass,et al. LightCycler technology for the quantitation of bcr/abl fusion transcripts. , 1999, Cancer research.
[23] I. Bièche,et al. Quantitation of MYC gene expression in sporadic breast tumors with a real-time reverse transcription-PCR assay. , 1999, Cancer research.
[24] P. De Giuli,et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. , 1998, Cancer research.
[25] S. Savin,et al. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. , 1998, Anticancer research.
[26] L. Baum,et al. Galectins: versatile modulators of cell adhesion, cell proliferation, and cell death , 1998, Journal of Molecular Medicine.
[27] E. Campo,et al. GALECTIN‐3 AND LAMININ EXPRESSION IN NEOPLASTIC AND NON‐NEOPLASTIC THYROID TISSUE , 1997, The Journal of pathology.
[28] E. Chi,et al. Expression and function of galectin-3, a beta-galactoside-binding lectin, in human monocytes and macrophages. , 1995, The American journal of pathology.
[29] R. Lotan,et al. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Potential diagnostic implications. , 1995, The American journal of pathology.
[30] A. Fusco,et al. Expression of galectin‐1 in normal human thyroid gland and in differentiated and poorly differentiated thyroid tumors , 1995, International journal of cancer.
[31] R. Bresalier,et al. Expression of an endogenous galactose-binding lectin correlates with neoplastic progression in the colon. , 1995, Cancer.
[32] S. Barondes,et al. Galectins. Structure and function of a large family of animal lectins. , 1994, The Journal of biological chemistry.